(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
1. A capsule containing
or a pharmaceutically acceptable salt thereof.
2. The capsule of claim 1 , wherein the capsule contains from 1 mg to 1000 mg of
or a pharmaceutically acceptable salt thereof.
3. The capsule of claim 1 , wherein the capsule contains from 25 mg to 500 mg of
or a pharmaceutically acceptable salt thereof.
4. The capsule of claim 1 , wherein the capsule contains
5. The capsule of claim 1 , wherein the capsule contains from 1 mg to 1000 mg of
6. The capsule of claim 1 , wherein the capsule contains from 25 mg to 500 mg of
7. A pill containing
or a pharmaceutically acceptable salt thereof.
8. The pill of claim 7 , wherein the pill contains from 1 mg to 1000 mg of
or a pharmaceutically acceptable salt thereof.
9. The pill of claim 7 , wherein the pill contains from 25 mg to 500 mg of
or a pharmaceutically acceptable salt thereof.
10. The pill of claim 7 , wherein the pill contains
11. The pill of claim 7 , wherein the pill contains from 1 mg to 1000 mg of
12. The pill of claim 7 , wherein the pill contains from 25 mg to 500 mg of
13. A tablet containing
or a pharmaceutically acceptable salt thereof.
14. The tablet of claim 13 , wherein the tablet contains from 1 mg to 1000 mg of
or a pharmaceutically acceptable salt thereof.
15. The tablet of claim 13 , wherein the tablet contains from 25 mg to 500 mg of
or a pharmaceutically acceptable salt thereof.
16. The tablet of claim 13 , wherein the tablet contains
17. The tablet of claim 13 , wherein the tablet contains from 1 mg to 1000 mg of
18. The tablet of claim 13 , wherein the tablet contains from 25 mg to 500 mg of